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ABSTRACT
Cell state-, developmental stage-, and lineage-speciﬁc combinatorial expression of cluster of dif-
ferentiation (CD) molecules enables the identiﬁcation of cellular subsets via multicolor ﬂow cyto-
metry. We describe an exhaustive characterization of neural cell types by surface antigens,
exploiting human pluripotent stem cell-derived neural cell systems. Using multiwell screening
approaches followed by detailed validation of expression patterns and dynamics, we exemplify a
strategy for resolving cellular heterogeneity in stem cell paradigms. In addition to providing a cat-
alog of surface antigens expressed in the neural lineage, we identiﬁed the transferrin receptor-1
(CD71) to be differentially expressed in neural stem cells and differentiated neurons. In this con-
text, we describe a role for N-Myc proto-oncogene (MYCN) in maintaining CD71 expression in pro-
liferating neural cells. We report that in vitro human stem cell-derived neurons lack CD71 surface
expression and that the observed differential expression can be used to identify and enrich
CD71− neuronal derivatives from heterogeneous cultures. STEM CELLS 2019;00:1–14
SIGNIFICANCE STATEMENT
The current article illustrates the strategy to resolve cellular heterogeneity of human stem cell
paradigms by conducting comprehensive surface marker screens. The results unequivocally
underline the absence of the transferrin receptor protein-1/CD71 on differentiated neurons,
exploiting a broad range of different human neural in vitro differentiation models. This work
identiﬁes CD71 as a surface molecule of use for neural cell selection in biomedical stem cell
paradigms.
INTRODUCTION
In vitro stem cell systems are being extensively
used for a wide range of purposes, from studying
the basic biology of development to disease
modeling and cell therapy [1, 2]. The derivation
of human embryonic stem cell (hESC) lines [3]
and human induced pluripotent stem cells (hiP-
SCs) [4] has revolutionized concepts in devel-
opmental biology and biomedical research.
Through directed differentiation, pluripotent
sources can be used to generate somatic cell
derivatives of all three germ layers [3].
Multipotent stem cells derived using such an
approach can be further differentiated into
deﬁned lineages by providing recombinant factors
or small molecule compounds in a time-dependent
manner. Although considerable progress has been
made in optimizing differentiation protocols, the
inherent heterogeneity of stem cell-derived prod-
ucts remains an impediment to biomedical appli-
cation. Stem cell research can greatly beneﬁt
from enhanced insights into the microenviron-
mental cues governing cell proliferation and phe-
notype establishment. Growth factor signals,
cell-matrix, and cell–cell interactions converge
onto surface molecule-mediated downstream
pathways, the speciﬁcs of which remain poorly
understood [5]. Furthermore, characteristic com-
binations of surface molecules can serve to
identify and isolate speciﬁc cellular subsets
by ﬂuorescence-activated cell sorting (FACS) or
immunomagnetic cell separation [6–8].
Neural stem/precursor cells (NSCs) derived
from hESCs and hiPSCs can be expanded and
maintained in their multipotent state in the
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presence of growth factors [9]. By adding speciﬁc differentia-
tion cues, NSCs can be differentiated toward neuronal and glial
central nervous system cell types [10] as well as neural crest
(NCR) derivatives [11, 12]. Inadequate in vitro patterning and dif-
ferentiation can result in cellular heterogeneity, thereby generat-
ing considerable variability in downstream applications [8, 13].
Unwanted contaminating cells introduce inconsistencies and may
affect subsequent scientiﬁc interpretation. Although the trans-
plantation of neurons/neuroblasts (NEU) derived from human
PSCs is on the verge of becoming a clinical reality for treating
neurodegenerative disorders [14–16], residual proliferating NSCs
can form tumors and yield unwanted deleterious progeny in vivo
[17, 18]. Therefore, eliminating unwanted cells and enriching the
cell type of interest will be critical for biomedical in vitro assays,
developmental studies and cell therapeutic paradigms alike. The
isolation of speciﬁc neural cell types using cluster of differentia-
tion (CD) antigens expressed on the cell surface has been
established as a proof of principle [8, 19–21]. However, a full
characterization of the neural surfaceome is currently not
available [22]. By exploiting a range of complementary sys-
tems ncluding hESCs, long-term expandable NSCs derived from
hiPSCs and immortalized neural precursor cell lines, we performed
a comprehensive analysis of neural CD antigen expression.
One of the differentially expressed marker candidates was
more extensively investigated to exemplify the validity of our
screening strategy. The CD71 epitope representing the transferrin
receptor protein 1 (TFR1) is a key regulator of transferrin-
dependent iron uptake in normal development and disease. CD71
(TFR1), a type II membrane glycoprotein, is expressed as a
disulﬁde-linked homodimer on the cell surface, binds to iron-bound
transferrin (holo-transferrin) and is internalized through receptor-
mediated endocytosis [23]. Most notably, CD71 plays a central role
to iron acquisition in erythroid precursors [24], but the protein is
expressed on a broad range of cell types at varying levels [25].
Rodent model studies indicated the presence of CD71 in neurons
and consider transferrin- and TFR1-dependent iron uptake as a
major pathway for neural iron homeostasis [26, 27]. Our data
reveal a signiﬁcant downregulation of CD71 upon neuronal differ-
entiation in a range of human in vitro systems. Maintenance of
CD71 expression in proliferative neural cells was found to be
dependent on the basic helix–loop–helix transcription factor N-
Myc proto-oncogene (MYCN), an indispensable mediator of neural
development [28]. CD71-negative (CD71−) cells lacked MYCN and
other neural stemness markers. Consequently, we adapted our
ﬁndings to develop a CD71-based neuronal selective vulnerability
assay as well as a single marker-based cell isolation strategy, both
of which may contribute to optimizing in vitro analytical readout
and (therapeutic) cell selection approaches in NSC biology.
MATERIALS AND METHODS
Maintenance of Cell Lines
For cell lines and reagents, see Supporting Information Tables S7
and S8. iPSC-NSC (AF22) and Lund human mesencephalic
(LUHMES)-NPC cells were cultured as described previously
[9, 11, 29]. PSCs (H9 and iPS-IMR90-4) were grown on feeder
cells and under feeder-free conditions. SNB-19 astroglial cells
were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
+10% fetal bovine serum [30]. Details are provided in Supporting
Information Experimental Procedures.
Neural Induction and hESC-NSC and NCR Expansion
H9 hESC (WA09, WiCell) were enzymatically harvested using
TrypLE and replated on Synthemax-coated 6-well plates at a den-
sity of 2 × 106 cells per well. Cells were grown overnight in E8
medium and switched to E8 containing 1 μM dorsomorphin and
10 μM SB431542 on the next day to initiate neural induction, with
a gradual shift (over 4 days) from an E8-based to DMEM:F12
(1:1) + N2 (1×) supplement-based medium containing dors-
omorphin and SB431542 at the aforementioned concentration.
On day 12, cells were TrypLE-passaged onto poly-ornithine/laminin
(PO/L)-coated tissue culture ﬂasks and maintained as NSCs in
DMEM:F12 with N2 (1×), 20 ng/ml bFGF and 20 ng/ml EGF.
Media was changed every day and NSCs were passaged at a
seeding density of 500,000 cells per cm2 every 3 to 4 days [11].
NCR cells were derived from hESC-NSC by applying low seeding
density over multiple passages as previously published [11].
Neuronal Differentiation
For hiPSC- and hESC-NSC cultures, a differentiation protocol of
14 days was applied. Long-term expandable hiPSC-NSC (AF22)
were differentiated by removing growth factor-containing media
and replacing it with differentiation media consisting of 50%
DMEM:F12-N2 and 50% Neurobasal-B27, including 100 U/ml
penicillin–streptomycin [11]. hESC-NSC were plated on PO/L-
coated plates at a density of 200,000 cells per cm2. One day after
plating, growth factor media was replaced with Neurobasal-B27
containing 20 ng/ml brain-derived neurotrophic factor 20 ng/ml
glial cell line-derived neurotrophic factor (GDNF), 200 μM ascorbic
acid, 0.5 mM dibutyryl cAMP, and 2 mM L-glutamine. For terminal
differentiation, cells were cultured for 14 days with media being
changed every other day. Fresh laminin at a ﬁnal concentration of
2 μg/ml was added every 4 days. To generate neural cultures
enriched for dopamine neurons, established protocols were
used [13, 31]. LUHMES-NPC cells were differentiated in DMEM:
F12-N2 medium with 1 μg/ml tetracyclin, 1 mM dibutyryl cAMP,
and 2 ng/ml GDNF for 6 days [29].
High-Throughput Flow Cytometric Screen and
Candidate Validation
Human neural cells obtained from proliferation and differentia-
tion conditions were screened for the expression of cell surface
molecules using human BD Lyoplate screening panels as recently
reported for neuroblastoma cells [32]. For ﬂow cytometric analy-
sis, single cell suspensions were dispensed into 96-well plates at
200,000–500,000 cells per well. Details of sample preparation for
ﬂow cytometry, cell sorting, and the antibodies (Supporting Infor-
mation Table S7) used are provided in Supporting Information
Experimental Procedures.
Immunoﬂuorescence and Western Blot Analysis
For details of immunocytochemistry, Western blot protocols
and antibodies (Supporting Information Table S8) used, please
refer to Supporting Information Experimental Procedures.
RESULTS
Cellular Heterogeneity of Neural Stem Cell
Differentiation Systems
The goal of the present study was to identify CD surface marker
signatures associated with human PSC neural lineage differ-
entiation that would be generally applicable across cell lines
©2019 The Authors. STEM CELLS published by
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independent of protocols and provenance. To this end, NSCs from
two human pluripotent sources were differentiated toward neuro-
nal phenotype (NEU) using deﬁned in vitro protocols [9, 11, 13]
(Fig. 1A). hESC-NSC and hiPSC-derived long-term expandable NSC
(hiPSC-NSC; AF22) [9] cultures were predominantly SOX2 (SRY-Box
2)-positive (SOX2+), whereas neuronally differentiated cultures
derived from either line (hESC-NEU and hiPSC-NEU) were largely
positive for β-III-tubulin (TUJ1+), with few remaining interspersed
SOX2+ NSC (Fig. 1B). This was conﬁrmed by Western blot analy-
sis, documenting an increase of TUJ1 and the mature
neuronal markers synapsin and microtubule-associated pro-
tein 2 (MAP2; Fig. 1C). Still, quantitative analysis showed a mere
≥65% of TUJ1- and ≥35% MAP2-positive cells in either system
(Supporting Information Fig. S1) highlighting the developmental
heterogeneity of in vitro neural differentiation paradigms and
the need to identify cell surface markers capable of distinguishing
the various maturation stages (NSC vs. NEU). In line with previous
reports [8, 19], cellular contaminants expressing neural stemness
(ZO-1, MYCN), astroglial glial ﬁbrillary acidic protein (GFAP), and
mesenchymal/NCR derivatives (ZEB1, Yes-associated protein (YAP),
Figure 1. Human pluripotent stem cell-derived neuronal differentiation systems exhibit cell stage- and cell state-associated phenotypic
heterogeneity. (A): Schematic outline of the neural induction and differentiation protocols used to derive proliferating neural stem cells
(NSCs) and differentiated neurons (NEU) from pluripotent stem cell (PSC) sources. (B): Immunocytochemistry for the NSC marker SOX2
(red) costained with the neural differentiation marker TUJ1 (green) on human embryonic stem cell- as well as hiPSC-derived proliferating
NSC and differentiated NEU. Scale bars: 50 μm. (C): Western blot analysis for expression of key cell signaling pathway proteins (MAPK,
AKT, JNK, hippo), neural differentiation (synapsin, MAP2, TUJ1, peripherin, ZEB1, GFAP), and proliferation (MYCN, ZO-1) markers.
www.StemCells.com ©2019 The Authors. STEM CELLS published by
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peripherin) also contribute to the phenotypic diversity of neu-
ronally differentiated cultures (Fig. 1C). In hiPSC-NEU, a larger pro-
portion of undifferentiated cells was observed as illustrated by the
presence of SOX2+ cells (Fig. 1B) and an enhanced MYCN expres-
sion compared with hESC-NEU (Fig. 1C). To determine subtle, yet
functionally relevant variances within and across hESC- and hiPSC-
based differentiation systems, a conﬁned analysis of key cell signal-
ing pathways was conducted. Most prominent differences were
identiﬁed in the activity of MAPK/ERK signaling, yet the expression
and activity of other signaling pathways such as AKT and
Hippo/YAP also differed between cell systems (Fig. 1C). Taken
together, these data illustrate the inherent heterogeneity with
respect to cell stage as well as cell state in PSC-derived neural dif-
ferentiation systems.
High-Throughput Cell Surface Antigen Screens of
Human Neural Stem Cells and Neurons
Unlike for the hematopoietic lineage, only a limited number of cell
surface antigens has previously been assessed on human neural
cells [6, 8, 11, 19, 21, 33, 34]. To identify novel neural lineage
markers, complementing proteomics approaches [22], a compre-
hensive high-throughput human cell surface antigen screen was
conducted. Most antigens analyzed using the screening panel
(BD Lyoplate) are classiﬁed under the CD nomenclature [35] and
have been frequently used for immunophenotyping. Applying a
threshold of ≥5% as the mean percentage of positive cells, hESC-
NSC, hESC-NEU, hiPSC-NSC, and hiPSC-NEU cells were screened for
the expression of 242 human cell surface antigens (Supporting
Information Fig. S2, Supporting Information Table S3). Of these, a
mere 147 were expressed in at least one of the cell systems
(Fig. 2A). We further assessed the antigens detected on each of
the four cell sources individually and collectively, which helped
identify the number of antigens expressed across hESC- and hiPSC-
based cell systems (Fig. 2B, marked in green). These 79 antigens
were classiﬁed as bona ﬁde, globally applicable “neural cell surface
antigens.” The remaining 68 antigens expressed in only a subset of
the cell sources tested, while not necessarily irrelevant, were
neglected for the purpose of the current study. CD numbers simply
represent a broadly accepted alternative terminology for known
proteins, carbohydrates, and lipid epitopes expressed on the cell
surface. Using the HUGO Gene Nomenclature Committee (HGNC)
database, CD numbers were converted to their ofﬁcial gene names
for subsequent gene ontology (GO) analysis [36]. Such processing
allowed for the functional annotation of the identiﬁed neural sur-
face antigens focusing on their involvement in biological pro-
cesses. Supporting Information Table S1 provides the complete
neural CD antigen list with the corresponding ofﬁcial name, sym-
bol, alternate names, HGNC ID, and Gene ID. Interactions with
viruses, cell proliferation, and signal transduction were identiﬁed
as the most signiﬁcant biological functions of the identiﬁed neural
surface antigens (Fig. 2C). As part of our current scope, Supporting
Information Figure S3A focuses on the surface molecules known
to participate in the process of cell proliferation. To hone in and
identify potential stage-speciﬁc markers for neural proliferation
versus differentiation (NSC vs. NEU), ﬂow cytometric validation of
CD antigen expression patterns was pursued next.
Decrease of CD71 (TFR1) and CD49b (ITGA2) Surface
Expression upon Neural Differentiation
High-throughput screening and subsequent comparative analysis
helped determine CD antigen candidates for low-throughput
characterization. A combination of arbitrarily selected 26 candi-
dates and three known lineage-speciﬁc markers was further
validated by ﬂow cytometry on neural stem cells (hESC-NSC;
hiPSC-NSC) and neurons (hESC-NEU; hiPSC-NEU; Fig. 3A,3B;
Supporting Information Table S4). Nineteen additional antigens,
some of which were not part of the initial screen, were also
included (Supporting Information Fig. S3B,S3C). Altogether, a sys-
tematic expression analysis of 48 cell surface antigens was per-
formed in comparison of human neural proliferation versus
neuronal differentiation. This merely represents a starting
point for neural surfaceome studies, the conﬁrmatory analysis
of 37 antigens identiﬁed by the initial screen to be expressed
across neural cell systems remains to be conducted.
We were able to conﬁrm the presence of known neural line-
age CD markers such as CD15 (SSEA-1), CD24, CD29 (ITGB1),
CD44, CD49d (ITGA4), CD171 (L1CAM), CD184 (CXCR4), and
CD271 (p75; NGFR) [8, 11, 19]. Low frequencies of the oligoden-
drocyte precursor marker CD140a and the postmitotic oligoden-
drocyte marker O4 [37], suggest minimal oligodendrocyte
contamination in all neural cell sources analyzed here. Other
markers were only seen in one of the cell systems. The overall
higher number of A2B5+ cells in hiPSC- versus hESC-derived neu-
ral cultures may reﬂect the greater proportion of neuroepithelial
cells [38]. Similarly, presence of CD54 (ICAM1) was only evident
in hiPSC, with higher levels at the NSC stage (Fig. 3A,3B). Upon
neuronal differentiation, expression levels of CD24 and CD184
increased in hiPSC, while remaining largely stable in hESC neural
differentiation. On the other hand, an increase in the number of
CD171+ and CD271+ cells was only seen in hESC-NSC/NEU
(Fig. 3B). These observations underline the need for screening
approaches exploiting multiple in vitro cell systems when aiming
to identify generally applicable neural markers.
The CD133 (Prominin1; PROM1), CD49b (Integrin alpha2;
ITGA2), and CD71 (TFR1) antigens showed a signiﬁcantly reduced
surface expression in both systems. CD133 is routinely exploited
to isolate multipotent stem cells from normal and cancerous tis-
sue [39], including NSC [40]. However, downregulation of CD133
expression (Fig. 3A) has also been observed as NSC enter a dorm-
ant/slow-cycling G0/G1 phase of their cell cycle [41]. Therefore,
CD133-negativity alone cannot be used as a hallmark for neural
differentiation. The CD71 and CD49b antigens were identiﬁed as
novel differentially expressed CD antigens (Fig. 3A,3B). Univariate
histograms comparing the cell surface expression of CD49b and
CD71 show a clear overlap of the NEU peak with the negative
control (Fig. 3C,3D). The magnitude of change in cell surface
expression for both markers was further quantiﬁed by comparing
the corresponding mean ﬂuorescence intensities (MFIs). Both
CD49b and CD71 showed a signiﬁcant reduction in MFI upon
neuronal differentiation (Fig. 3D,3E; Supporting Information
Fig. S4A,S4B). The low MFI levels observed in NEU cultures, we
believe, are the cumulative effect of potential undifferentiated
NSC or contaminant cells like NCR, astroglial cells in our in vitro
NEU-cell culture system. So far, only resting lymphocytes and
mature erythrocytes have been characterized by a lack cell sur-
face CD71 [42].
Absence of CD71 (TFR1) Protein upon Neuronal In Vitro
Differentiation
Transferrin/TFR1-dependent iron uptake plays a key role in iron
homeostasis and receptor-mediated endocytosis, involving in a
continuous shuttling of the protein between the cell membrane
©2019 The Authors. STEM CELLS published by
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and the cytoplasm [23]. As MFI-based ﬂow cytometric quantiﬁca-
tion only takes into consideration the presence of the protein at
the cell surface, the observed reduction could be solely due to
the internalization of the receptor upon differentiation. Imaging
and Western blot analyses were conducted to compare total pro-
tein levels. We observed strong CD71 expression on SOX2+ NSC
but not on TUJ1+ NEU cells (Fig. 4A,4B; Supporting Information
Fig. S4C–S4D). Similarly, total protein analysis showed a
Figure 2. Comprehensive surface molecule screening reveals markers associated with human neural lineage development and function-
ality. (A): Heatmap depicting the mean percentage of cells positive for each cluster of differentiation (CD) antigen (color-coded bar). The
dataset was generated via high-throughput ﬂow cytometric screens of 242 human cell surface antigens in human embryonic stem cell- as
well as hiPSC-derived proliferating neural stem cell (NSC) versus differentiated neurons, neurons/neuroblasts (NEU; BD Lyoplate; cutoff
threshold ≥5% positivity; n ≥ 2). (B): Venn diagram comparing the number of cell surface antigens exclusively expressed and/or shared
(intersection) among the four different neural cell samples. Labeled in green are the antigens newly classiﬁed as “neural cell surface anti-
gens.” The area shaded in gray highlights generalizable neural surface antigens detected in any of the PSC-derived neural cell samples
analyzed. (C): Biological functional annotation obtained after transformation of neural CD antigen nomenclature into gene
names/accession numbers (Supporting Information Table S1), arranged from highest to lowest enrichment score (high enrichment
score ~ lowest p-value/highest signiﬁcance).
www.StemCells.com ©2019 The Authors. STEM CELLS published by
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prominent decrease in CD71 protein levels between NSCs and
NEU (Fig. 4C). The reduction was more profound in hESC-derived
cells than in hiPSC-derived cells, reﬂecting the maintained pres-
ence of undifferentiated, glial, and NCR cells in the hiPSC-NEU
cultures, as indicated by the higher levels of SOX2 (Figs. 1B, 4C,
Supporting Information Fig. S4F), MYCN (Fig. 1C) and CD44
(Supporting Information Fig. S4E). Corroborating our cell surface
data, CD49b was also downregulated upon neural differentiation
(Fig. 4C). To further conﬁrm our ﬁndings, and also in light of
potential biomedical utility, we used three independent dopami-
nergic (DA) in vitro systems: hESC, hiPSC (iPS-IMR90)-derived DA
neurons (hESC-DA-NEU) [31], and the LUHMES-neural precursor
cell line (LUHMES-NPC) [29]. Exploiting LUHMES cells, a drug-
inducible DA differentiation system, we once again observed a
signiﬁcant reduction in the number of both CD71+ and CD49b+
cells upon neuronal differentiation (Fig. 4D). This was corrobo-
rated by the magnitude of cell surface expression change of both
proteins (MFI; Supporting Information Fig. S5A,S5B). Similarly, at
the total protein level, MAP2-negative LUHMES-NPC expressed
CD71 at high levels whereas MAP2+/tyrosine hydroxylase (TH)+/
TUJ1+ LUHMES-NEU, hESC-DA-NEU, and MAP2+ non-DA hESC-
NEU barely showed any expression (immunoblot, also conﬁrmed
by immunocytochemistry; Supporting Information Fig. S5C,S5D).
In hiPSC (iPS-IMR90)-derived DA neuronal differentiation
cultures, a clear reduction of CD71 expression in comparison to
the DA precursor cultures was seen (Supporting Information
Fig. S5F). Low levels of CD71 expression detected in immuno-
blots correspond well with the considerable number of CD49b+
and CD71+ cells remaining present at the differentiation stage in
PSC-derived systems (Supporting Information Fig. S5E). From
these sets of experiments, we could conﬁdently conclude that
in vitro derived human-NEU do not express CD71 (TFR1).
N-Myc Regulates CD71 (TFR1) Expression on
Proliferating Neural Cells
N-Myc (MYCN) governs one of the key gene networks critical for
normal brain development [28] and knockdown of MYCN leads to
embryonic lethality [43, 44]. Myc proteins regulate the expression
of their targets by binding to regulatory elements of the gene,
predominantly the E-box consensus binding sites [45]. Studies
using B-lymphocytes have previously identiﬁed c-Myc (MYCC) to
bind E-box sequences upstream of the TFR1 gene [46]. However,
any potential role of MYCN in regulating CD71 expression on pro-
liferating neural cells has not been addressed. To this end, we
conducted a siRNA-mediated knockdown (KD) of MYCN in hESC-
NSC (Fig. 4E) and a MYCN-ampliﬁed neuroblastoma cell line
(Fig. 4H), were we also observe a co-expression of MYCN with
CD71 (Supporting Information Fig. S6B). Unlike neuroblastoma
Figure 3. Cell surface expression of the CD71 (TFR1) and CD49b (ITGA2) antigens is downregulated upon neuronal differentiation. (A, B):
Flow cytometric validation of cell surface antigen expression on human embryonic stem cell- and human induced pluripotent stem cell-
derived neural cells (neural stem cell [NSC]: blue and neurons/neuroblasts [NEU]: red). Bar graphs show the mean percentage of positive
cells (X-axis) for individual CD antigens (Y-axis; n ≥ 3). (C, E): Univariate histograms representing the number of CD49b- and CD71-expressing
cells in NSC (blue) versus NEU (red) plotted against negative controls (black), indicating the absence of CD71 and CD49b surface expression.
(D, F): Magnitude of change in cell surface CD49b and CD71 as quantiﬁed by mean ﬂuorescence intensity, showing a signiﬁcant reduction of
both markers upon neural differentiation (n ≥ 3; *, p < .05; **, p ≤ .01; ***, p ≤ .001; unpaired Student’s t test).
©2019 The Authors. STEM CELLS published by
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Figure 4. Alteration in total protein expression of CD71 (TFR1) and CD49b (ITGA2) upon neuronal differentiation and MYCN-knock-
down. (A): Immunocytochemistry for CD71 (red), costained with neural stem/precursor cell (NSC)-marker SOX2 (green) in human
embryonic stem cell (hESC)-NSC. (B): hESC-neurons/neuroblasts (NEU) stained for CD71 (red) and NEU/NB-marker TUJ1 (green); Hoechst
(blue: nuclei). (C): Western blot analysis of NSC and NEU derived from hESC and hiPSC. Samples were probed for EGFR, CD71, Twist1,
CD49b, and SOX2; loading control: GAPDH. (D): Proliferative LUHMES midbrain precursor cells (NPC) and differentiated LUHMES cells
(NEU) analyzed by ﬂow cytometry for CD71 and CD49b surface expression. The bar graph represents the mean percentage of positive
cells for both markers (n ≥ 4). (E): Western blotting for siRNA-mediated knockdown (KD) of MYCN in hESC-NSC. (F, G): Quantiﬁcation
shows a signiﬁcant downregulation of MYCN and TFR1 (n = 3). (H): MYCN-KD in MYCN ampliﬁed neuroblastoma cell line BE(2)-M17.
Immunoblotting demonstrates the downregulation of CD71, MYCN, and Twist1 upon MYCN knockdown. Scrambled siRNA (siSCRL) and
GAPDH were used as controls. (I, J, K): Western blot quantiﬁcation for MYCN, CD71, and Twist1 post-MYCN-KD (n = 6). (L): Flow
cytometric quantiﬁcation of TrKA expression upon MYCN-KD showed a signiﬁcant increase in the number of TrKA+ cells (n = 3). Knock-
down of MYCN (N-Myc) signiﬁcantly downregulated CD71 (TFR1) expression (scale bar: 20 μM; *, p < .05; **, p ≤ .01; ***, p ≤ .001;
unpaired Student’s t test).
www.StemCells.com ©2019 The Authors. STEM CELLS published by
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cells, hESC-NSC cells were prone to cell death when exposed to
high doses of MYCN siRNA. Therefore, hESC-NSCs were exposed
to a subthreshold siRNA concentration to achieve a conservative
2.9-fold KD of MYCN (Fig. 4F). As a consequence of MYCN-KD a
signiﬁcant decrease in CD71 (TFR1) protein was observed (Fig. 4G).
A profound KD (11.4-fold) of MYCN protein could be achieved
on neuroblastoma cells using the siRNA approach (Fig. 4I), which
resulted in a signiﬁcant downregulation of CD71 (Fig. 4J) and
Twist1 (Fig. 4K) total protein expression. Twist1 was used as the
positive control for the assay, as it a well-characterized direct tran-
scriptional target of MYCN [47]. In contrast to the effect on CD71
(TFR1), we observed an increase in CD49b (ITGA2) as well as TrkA
expression upon MYCN-KD (Fig. 4E,4H,4L). An increase in TrKA-
positivity as a consequence of MYCN inhibition is well established
for neuroblastoma [48]. Treatment of NSC’s with revers-
ible (Roscovitine) and irreversible (Mitomycin C) proliferation
inhibitors (Supporting Information Fig. S7A,S7C) which do not
directly target MYCN-proliferation network were unable to inﬂu-
ence CD71 expression (Supporting Information Fig. S7B,S7C). Our
data therefore suggest that the MYCN-gene regulatory network,
and not the proliferative network alone of a cell, is critical for the
expression of CD71 (TFR1) in proliferating neural cells, yet
whether this occurs by directly binding to its upstream E-box or
via an indirect pathway remains to be elucidated.
Pluripotent Stem Cells, NCR, and Astroglial Cells
Express High Levels of CD71 (TFR1)
Undifferentiated NSCs within neuronally differentiated cultures
represent merely one of the contributors to cellular heterogene-
ity. Other key contaminants include PSC that failed to undergo
neural induction as well as NCR and astroglial cells [18, 19]. To
evaluate the possibility of using negativity for CD71 or CD49b to
isolate NEU cells from heterogeneous cultures, we assessed the
expression of these marker candidates on neural in vitro culture
contaminants. Importantly, both pluripotent stage hESC and
hESC-NCR cells expressed CD71 and CD49b on their surface
(≥85% of cells; Fig. 5A). As determined by MFI, human hESC-NCR
exhibited a higher expression level per cell of the migration-
associated integrin subunit CD49b in comparison to pluripotent
stage hESC, which was also veriﬁed by Western blotting
(Fig. 5B,5C). Although vimentin+/Twist1+/SOX2− hESC-NCR also
seemed to have higher CD71 total protein expression, this differ-
ence was not signiﬁcant at the cell surface (Fig. 5B,5D). Hence,
the higher cell surface levels of CD49b (ITGA2) could potentially
be exploited to distinguish NCR cells (CD71+/CD49bhigh) from
hESC, and NSC (both CD71+/CD49b+) as well as NEU (CD71−/
CD49b−). Astrocytes generated from NSCs [49] and the glioblas-
toma cell line SNB-19 were explored to quantify the expression
of CD71 and CD49b in the astroglial lineage. Prominent CD71
and CD49b expression was observed (Fig. 5E) and immunocyto-
chemistry showed coexpression of the glial marker GFAP with
CD71 in YAP+/ZO-1+/vimentin+/MAP2−, PSC-derived astrocytes
as well as SNB-19 cells (Fig. 5F, Supporting Information Fig. S8A)
For CD71, a clear positive correlation with cell proliferation is
already known, as it is often overexpressed on a wide range of
malignant tissues including glioma, neuroblastoma and colon
and pancreatic cancers [50, 51]. As a result, various anti-TFR1
(CD71) tumor-targeting approaches have been developed
[52, 53]. Gambogic acid (GA), a naturally occurring, potent anti-
cancer agent [54], is one of the compounds known to trigger
apoptosis by binding to TFR1 [55]. In the context of our study,
we treated in vitro neural cultures with GA, which resulted in the
induction of apoptosis of in vitro hiPSC-NSC, but not of CD71−
hiPSC-NEU. GA at a minimum concentration of 2 μM caused a
considerable loss of cells in NSC culture (Fig. 5G,5H) within
3 hours, whereas this effect was not observed in neuronally dif-
ferentiated cells even at a concentration of 4 μM (Fig. 5G,
Supporting Information Fig. S8B). Apoptosis was also triggered in
other CD71+ multipotent neural cells (hESC-NSC; hESC-NCR) and
pluripotent stem cells (hESC; Fig. 5I). In contrast, we did not
observe cell loss of differentiated neuronal cultures (LUHMES-
NEU, hESC-NEU, hiPSC-NEU) when exposed to the identical treat-
ment paradigm (Fig. 5J). Thus, the lack of a toxic response to the
known TFR1-ligand GA further underlines the absence of func-
tional expression of the CD71 antigen on differentiated neuronal
cells.
CD71 (TFR1) as a Marker to Evaluate Cell Type-Speciﬁc
Vulnerability for Cytotoxic Compounds
Drug screening platforms heavily rely on human in vitro cell
models to evaluate the action of the respective compounds. In
order to examine the options of using CD71 as a marker for
selective vulnerability studies, we used A23187, a calcium iono-
phore with deﬁned neurotoxic activity [13]. Using a previously
established protocol [31], TH+/synapsin+ DA neuronal (hESC-DA-
NEU) cultures, also containing a small fraction of undifferentiated
OTX2+/SOX2+ DA precursors, were derived for the assay
(Fig. 6A). Cells were treated with known DA-NEU toxins A23187,
ferrous chloride (FeCl2), and DMSO (vehicle control). Treatment
with A23187 resulted in a loss of the neural network, retraction
of neurites (Fig. 6B), and signiﬁcant cell death. After treatment,
live cells were analyzed for a combination of surface proteins.
A signiﬁcantly higher number of CD71+ viable cells were identi-
ﬁed post-A23187 treatment (Fig. 6C). Considerable variability in
the number of CD49b+ cells was observed under control condi-
tion and no signiﬁcant difference was detected post-A23187
treatment, pointing to a potential variability of CD49b expression
patterns in DA neurons (Fig. 6C). No change was observed with
respect to CD166 (ALCAM), a DA precursor/neuron marker
[6, 34], which we found to also be expressed by NCR (Fig. 5A).
Consistent with our observations, treatment with A23187
resulted in the loss of TH+/synapsin+/MAP2+ DA neurons, repre-
sented by the CD71− fraction. Cells remaining in the dish after
A23187 treatments were positive for FOXA2, a DA precursor/
neuron marker as well as CD71 (Fig. 6D). Thus, using negativity
for CD71 as a surrogate marker, the selective cytotoxicity of small
molecules (such as A23187) toward mature neurons (DA-NEU)
can be can be assessed in pharmacological screens to rapidly
and quantitatively determine neuronal viability, susceptibility
and neuroprotection even in heterogeneous neural cell cul-
ture systems.
Isolation of NEU Fraction from Heterogeneous In Vitro
Neural Cultures Using Fluorescence-Based and
Magnetic Immunoseparation
Following the conﬁrmation that CD71 and CD49b are expressed
on PSC, NSC, and NCR but not on NEU, we exploited the identi-
ﬁed difference to develop novel cell selection strategies. Current
NEU cell isolation either requires a combination of cell surface
markers or multiple FACS experiments to enrich the target cell
[8, 13, 19]. We isolated CD71+/CD49b+ and CD71−/CD49b− sub-
populations from hESC-NEU cultures at 10 days of
©2019 The Authors. STEM CELLS published by
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Figure 5. CD71 (TFR1) and CD49b (ITGA2) are expressed on pluripotent stem cells (human embryonic stem cell [hESC]) neural crest (NCR)
and astroglial cells. (A): Pluripotent hESC and hESC-derived NCR cells analyzed by ﬂow cytometry for plasma membrane expression of CD49b,
CD71, CD90 (THY1), and CD166 (ALCAM; n ≥ 3). CD71 and CD49b expression is observed in >85% cells. (B): Validation of total protein expres-
sion of CD49b, vimentin, CD71, SOX2, OCT3/4, and Twist1. (C): Magnitude of cell surface CD49b expression quantiﬁed by mean ﬂuorescence
intensity (MFI; n ≥ 4). hESC-NCR show a signiﬁcantly higher surface expression of CD49b per cell. (D): CD71 expression quantiﬁed by ﬂuores-
cence intensity (MFI; n ≥ 4). (E): Flow cytometric analysis of hESC-derived astrocytes and SNB-19 glioblastoma cells (n = 3). (F): Immunocyto-
chemistry staining of glial cells for GFAP, CD71, and YAP. (G): Gambogic acid (GA) triggers cytotoxicity by targeting cell surface CD71 (TFR1).
Dose–response curve for cell viability of hiPSC-derived neural stem/precursor cell (NSC) and neurons/neuroblasts (NEU) treated with GA for
3 hours. (H): Estimation of live, preapoptotic and apoptotic cells by quantifying annexin-V/propidium iodide (n = 4). (I): Phase contrast images
comparing control (DMSO) versus GA treatment for CD71-expressing PSC, NSC, and NCR. (J): Phase contrast and immunocytochemistry of NEU
cells for control (DMSO) and GA treatments. When applied to CD71− NEU cells, GA treatment was unable to trigger a similar cytotoxic
response (scale bar: 50 μM; *, p < .05; **, p ≤ .01; ***, p ≤ .001; unpaired Student’s t test).
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differentiation using FACS. The CD71−/CD49b− population was
enriched for DCX+ and TUJ1+ NEU cells (Fig. 7A). DCX+/TUJ1+
were nearly absent in the CD71+/CD49b+ subset. To simplify the
sorting method and given the availability of CD71 antibody for
clinically approved magnetic immunoseparation, we next pur-
sued single-marker CD71-negative selection for NEU enrichment.
Having demonstrated the neuronal identity of CD71−/CD49b−
cells, we further assessed the coexpression of CD71 and CD49b in
order to evaluate the possibility of using CD49b-negative selection
alone as an additional strategy to enrich neurons. To this end,
CD49b expression was analyzed on the CD71+ and CD71− subpop-
ulations (Supporting Information Fig. S8C). Although the majority
(≥90%) of CD71+ cells were CD49b+, CD71− cells showed hetero-
geneous CD49b expression on their cell surface (Supporting
Information Fig. S8D). Furthermore, only a fraction (≤50%) of
CD49b-postive cells expressed CD71 (Supporting Information
Fig. S8E), thereby highlighting the inability of CD49b+ versus
CD49b− selection to provide optimal resolution for cell sorting.
Based on these ﬁndings and to simplify the sorting method,
hiPSC-NEU cells were subjected to CD71-negative versus positive
selection by FACS (Sort purity in Supporting Information Fig. S7D).
Similar to our previous observation the CD71− cell fraction
exhibited a TUJ1+/DCX+ neuronal phenotype (Fig. 7B). In contrast,
the CD71+ fraction comprised a mixture of Ki67+ proliferative cells
also positive for GFAP and nestin while being negative for
TUJ1 and DCX (Fig. 7B,7C). Five days post-CD71− sorting, the
viability and functionality of the isolated mature neurons
were evaluated by whole-cell current clamp (Supporting Infor-
mation Fig. S9). All recorded cells exhibited a clear neuronal
phenotype in which actions potentials could be evoked after
current injection (8/8 cells) or occurred spontaneously (5/8;
Supporting Information Fig. S9A), and showed clear neurites
extending from the soma (Supporting Information Fig. S9B). This
CD71− selection strategy was then replicated using immuno-
magnetic cell separation (MACS) on a heterogeneous mixture
of hESC-derived neural cells. The CD71− subset was Ki67−/
GFR1alpha+/high/MAP2+/synapsin+/TH+ and immunoreactive for
DCX as well as MAP2 highlighting the presence of NEU cells
(Fig. 7D,7E). These data illustrate that the selection of CD71− cells
represents a viable option to enrich for neuronally differentiated
cells in a range of neural differentiation systems. As previously
stated, CD71+ expression alone cannot distinguish between NSC,
Figure 6. Exploiting negativity for CD71 (TFR1) to assess selective vulnerability of neurons to cytotoxic small molecules. (A): Immunocy-
tochemistry staining of DA neurons (human embryonic stem cell [hESC]-dopaminergic [DA]-neurons/neuroblasts [NEU]) for TH, OTX2,
SOX2, and synapsin. (B): Phase contrast image of DA-NEU treated with vehicle control, FeCl2 (35 μM), and A23187 (2 μM) for 24 hours.
Cell death and disruption of neural network was observed upon A23187 treatment. (C): Post-treatment ﬂow cytometry-based analysis for
the expression of CD166, CD49b, CD147, and CD71. Post-A23187 treatment, a signiﬁcant number of viable cells was CD71 and CD166 pos-
itive (n = 4). (D): Western blotting analysis post-treatment (scale bar: 50 μM; *, p < .05; **, p ≤ .01; ***, p ≤ .001; one-way analysis of var-
iance with post hoc Tukey test).
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Figure 7. Using CD71− selection to isolate neuronal cells (neurons/neuroblasts [NEU]) from heterogeneous PSC-derived neural in vitro
cultures. (A): Immunocytochemistry and phase contrast images of CD49b+/CD71+ and CD49b−/CD71− subpopulations isolated by
ﬂuorescence-activated cell sorting (FACS). (B): FACS sorting CD71+ and CD71− cells from hiPSC-NEU cultures. DCX+ (Doublecortin) and
TUJ1+ NEU were enriched in the CD49b−/CD71− and CD71− only fractions. (C): Immunomagnetic separation of CD71+ and CD71− subpop-
ulations from heterogeneous neural cell cultures containing proliferating (neural stem/precursor cell/neural precursor cell) and differenti-
ated cells (NEU/NB). Separation was followed by Western blot analysis for the isolated subsets versus unsorted. The CD71− fraction was
Ki67−/synapsin+/MAP2+/TH+. (D): Immunocytochemical analysis of cellular subsets isolated via immunomagnetic cell separation and the
unsorted fraction. SOX2−/DCX+/MAP2+ cells were predominantly isolated in the CD71− subset (scale bar: 50 μM).
www.StemCells.com ©2019 The Authors. STEM CELLS published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press 2019
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NCR, and PSC. Hence, for better resolution between NCR versus
NSC and PSC, high CD49b expression could be exploited (Fig. 5C).
DISCUSSION
Cells express a plethora of antigens on their plasma mem-
brane. Intracellular transmission of external stimuli, cell adhe-
sion, and transport of cargo across the cell membrane are
among the common functions associated with cell surface mole-
cules. Characteristic combinations of these antigens can deﬁne
the identity of a cell. Hematopoietic and immunological research
has greatly beneﬁted from capitalizing on the extensive number
of lineage-deﬁning cell surface molecules [56, 57]. In contrast, for
the human neural lineage only a limited number of antigens
have been explored [7, 8, 19, 21]. The comprehensive in vitro
screening approach on multiple cell sources including postmitotic
neurons provided here represents a foundation for cataloging CD
marker expression dynamics on proliferating as well as differenti-
ated human neural cells.
Among the neural cell systems tested, 95 antigens of the
242 tested in the original screen were found to exhibit little to
no expression (<5% positive cells). These include known T cell
markers (CD4, CD5, CD6, CD8a/b, CD45) as well as antigen pre-
senting proteins (CD1a, CD1b, CD1d, CD83), CD62P (P-selectin),
CD274 (PD-L1), and CD279 (PD-1). Of the markers in fact iden-
tiﬁed as present on neural cells, the majority is prominently
involved in the interaction with viruses, cell proliferation, and
signal transduction (Fig. 2C). Of note, the deleterious effects of
infection by Zika and other neurotropic viruses on neural pre-
cursor cells have recently sparked an interest in studying the
participation of cell surface proteins in viral entry and suscepti-
bility of neural cells to such pathogens [58]. Many of the can-
didate surface antigens identiﬁed in this study, including the
CD71 (TFR1) have previous reported interactions with viruses
[59], and may therefore provide new leads toward future
research in these ﬁelds.
Expression of CD49b (integrin α-2; ITGA2) has previously
been observed on human NSCs [60], but follow-up analysis
regarding how levels may vary upon exiting the stem cell stage
has been limited. Although the current study focused on enrich-
ment of neurons, the expression pattern of CD49b (ITGA2) could
potentially be exploited as a marker for the enrichment of NCR
progeny. NCR cells were found to exhibit a signiﬁcantly higher
CD49b expression on their cell surface compared with NSC, NEU,
and PSC. Consequently, a CD71+/CD49bhigh cell selection strategy
could be used to isolate this cell type. To discriminate between
NSC and PSC in vitro, the CD71/CD49b code would have to be
combined with pluripotency-associated surface markers such as
SSEA-4, SSEA-3, and CD9 [61]. Thereby, one could deﬁne NEU
(CD71−/CD49b−), NCR (CD71+/CD49bhigh), NSC (CD71+/CD49b+;
SSEA-3/−4/CD9-negative), and PSC (CD71+/CD49b+; SSEA-3/−4/
CD9-positive).
Across multiple in vitro human neural cell systems, a signiﬁ-
cant reduction of CD71+ cells was observed upon neuronal differ-
entiation, the CD71 (TFR1) protein neither being expressed on the
cell surface nor intracellularly. Compared with CD49b, CD71
showed a less variable expression pattern (Supporting Information
Figs. S5E, S8C–S8E), a clear association with stemness (Fig. 4E–4G)
and a greater sensitivity for detecting neuronal cell loss (Fig. 6C).
As a consequence of its pivotal role in iron homeostasis, nearly all
cell types are expected to express CD71 on their cell surface,
although at varying levels [25]. Therefore, the observation that
in vitro human neurons are CD71− is unique from a biological per-
spective. In proliferating neural cells, the expression of CD71 was
identiﬁed to be dependent on MYCN activity, yet whether the
absence of CD71 in NEU is directly due to the downregulation of
the neural cell proliferation protein MYCN remains open.
Exploiting the differences in CD71 expression in the neural
lineage, we could highlight a simpliﬁed method to enrich neu-
rons and use CD71 as a marker for selective vulnerability
assays, in PSC-derived neural cultures. Cellular heterogeneity
of these in vitro cell systems remains a common concern in
disease modeling and cell therapy and developing strategies to
resolve this heterogeneity is an important necessity for the
advancement toward NSC-derived therapeutics [16, 20, 21].
The negative selection method toward elimination of Ki67+
proliferating cells and enrichment of neurons (CD71−) as well
as the described CD71-based cytotoxicity read-out can facili-
tate biomedical advancement in cell therapy and drug discov-
ery. Tissue level comparison of TFR1 transcript expression in
humans using Harmonizome database [62] further supports
the low presence of CD71 in CNS-neurons (Supporting Infor-
mation Fig. S6A).
Taken together, this study provides an exhaustive analysis of
neural CD surface antigen expression and describes CD71 as a
novel, differentially expressed surface marker in the neural line-
age. Beyond the utility of CD71 for cell selection, CD71-mediated
contribution to neural iron metabolism and differential suscepti-
bility to virus in human neurons lend themselves to future in-
depth investigation. Ultimately, the extended list of markers of
neuropoiesis may further aid in elucidating cell–cell interactions
involved in the regulation of growth and differentiation in neural
development, stemness, and cancer.
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